Is it Time to Expand the Use of SGLT2 Inhibitors in Kidney Transplant Recipients?
作者信息
Giri Kajaree, Dube Geoffrey K
机构信息
Department of Nephrology, Amor Hospitals, Hyderabad, Telangana, India.
Department of Medicine, Division of Nephrology, Columbia University Irving Medical Center, New York, New York, USA.
出版信息
Kidney Int Rep. 2025 Jan 10;10(3):660-662. doi: 10.1016/j.ekir.2025.01.007. eCollection 2025 Mar.
Abstract
摘要
相似文献
1
Is it Time to Expand the Use of SGLT2 Inhibitors in Kidney Transplant Recipients?是时候扩大钠-葡萄糖协同转运蛋白2抑制剂在肾移植受者中的应用了吗？
Kidney Int Rep. 2025 Jan 10;10(3):660-662. doi: 10.1016/j.ekir.2025.01.007. eCollection 2025 Mar.
2
The efficacy and safety of sodium-glucose cotransporter-2 inhibitors in solid organ transplant recipients: A scoping review.钠-葡萄糖共转运蛋白 2 抑制剂在实体器官移植受者中的疗效和安全性：范围综述。
Pharmacotherapy. 2024 Jun;44(6):444-466. doi: 10.1002/phar.2928. Epub 2024 May 21.
3
Use of sodium-glucose co-transporter 2 inhibitors in solid organ transplant recipients with pre-existing type 2 or post-transplantation diabetes mellitus: A systematic review.钠-葡萄糖协同转运蛋白2抑制剂在患有2型糖尿病或移植后糖尿病的实体器官移植受者中的应用：一项系统评价。
Transplant Rev (Orlando). 2023 Jan;37(1):100729. doi: 10.1016/j.trre.2022.100729. Epub 2022 Nov 4.
4
Are There Any Renoprotective Effects of SGLT2 Inhibitors in Heart Transplant Recipients with Diabetes?钠-葡萄糖协同转运蛋白2抑制剂对糖尿病心脏移植受者有肾脏保护作用吗？
Acta Cardiol Sin. 2025 Mar;41(2):242-250. doi: 10.6515/ACS.202503_41(2).20241111C.
5
Safety and Efficacy of Sodium-glucose Cotransporter 2 Inhibitors in Kidney Transplant Recipients With Pretransplant Type 2 Diabetes Mellitus: A Retrospective, Single-center, Inverse Probability of Treatment Weighting Analysis of 85 Transplant Patients.钠-葡萄糖协同转运蛋白2抑制剂在移植前患有2型糖尿病的肾移植受者中的安全性和有效性：一项对85例移植患者的回顾性、单中心、治疗权重逆概率分析
Transplant Direct. 2021 Oct 6;7(11):e772. doi: 10.1097/TXD.0000000000001228. eCollection 2021 Nov.
6
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.用于治疗肾移植受者既往存在的和新发糖尿病的降糖药物。
Cochrane Database Syst Rev. 2020 Jul 30;8(8):CD009966. doi: 10.1002/14651858.CD009966.pub3.
7
Combination of SGLT2 Inhibitors and GLP-1 Receptor Agonists in PTDM Treatment in Kidney Transplant Recipients: Synergistic Effect With Added Value in Terms of Nephroprotection.SGLT2 抑制剂与 GLP-1 受体激动剂联合治疗肾移植受者的 PTDM：在肾脏保护方面具有协同作用和附加价值。
Transplant Proc. 2024 Jul-Aug;56(6):1264-1265. doi: 10.1016/j.transproceed.2024.02.026. Epub 2024 Jul 27.
8
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibition in Kidney Transplant Recipients with Diabetes Mellitus.钠-葡萄糖共转运蛋白 2（SGLT2）抑制剂在糖尿病肾病移植受者中的应用。
Kidney Blood Press Res. 2019;44(5):984-992. doi: 10.1159/000501854. Epub 2019 Aug 22.
9
Review of Newer Antidiabetic Agents for Diabetes Management in Kidney Transplant Recipients.新型抗糖尿病药物在肾移植受者糖尿病管理中的应用评价。
Ann Pharmacother. 2021 Apr;55(4):496-508. doi: 10.1177/1060028020951955. Epub 2020 Aug 14.
10
Safety and Efficacy of Sodium-Glucose Transport Protein 2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Diabetic Kidney Transplant Recipients: Synthesis of Evidence.钠-葡萄糖转运蛋白2抑制剂和胰高血糖素样肽-1受体激动剂在糖尿病肾移植受者中的安全性和有效性：证据综述
J Clin Med. 2024 Oct 17;13(20):6181. doi: 10.3390/jcm13206181.
本文引用的文献
1
The outcomes of SGLT-2 inhibitor utilization in diabetic kidney transplant recipients.糖尿病肾移植受者中 SGLT-2 抑制剂应用的结局。
Nat Commun. 2024 Nov 20;15(1):10043. doi: 10.1038/s41467-024-54171-8.
2
Cardioprotective Effect of SGLT2 Inhibitor in Diabetic Kidney Transplant Recipients: A Multicenter Propensity Score Matched Study.钠-葡萄糖协同转运蛋白2抑制剂对糖尿病肾移植受者的心脏保护作用：一项多中心倾向评分匹配研究
Kidney Int Rep. 2024 May 25;9(8):2474-2483. doi: 10.1016/j.ekir.2024.05.022. eCollection 2024 Aug.
3
KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease.KDIGO 2024慢性肾脏病评估与管理临床实践指南
Kidney Int. 2024 Apr;105(4S):S117-S314. doi: 10.1016/j.kint.2023.10.018.
4
Sodium-glucose cotransporter-2 inhibitor therapy in kidney transplant patients with type 2 or post-transplant diabetes: an observational multicentre study.钠-葡萄糖协同转运蛋白2抑制剂治疗2型糖尿病或移植后糖尿病的肾移植患者：一项多中心观察性研究。
Clin Kidney J. 2023 Jan 11;16(6):1022-1034. doi: 10.1093/ckj/sfad007. eCollection 2023 Jun.
5
Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence.KDIGO 2022 慢性肾脏病糖尿病管理临床实践指南执行摘要：基于快速涌现的新证据的更新。
Kidney Int. 2022 Nov;102(5):990-999. doi: 10.1016/j.kint.2022.06.013.
6
The Efficacy and Safety of SGLT2 Inhibitor in Diabetic Kidney Transplant Recipients.SGLT2 抑制剂在糖尿病肾移植受者中的疗效和安全性。
Transplantation. 2022 Sep 1;106(9):e404-e412. doi: 10.1097/TP.0000000000004228. Epub 2022 Jun 30.
7
Sodium-glucose cotransporter 2 inhibitors for treatment of diabetes mellitus after kidney transplantation.钠-葡萄糖共转运蛋白 2 抑制剂在肾移植后治疗糖尿病中的应用。
Clin Transplant. 2022 Aug;36(8):e14718. doi: 10.1111/ctr.14718. Epub 2022 May 30.
8
Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial.达格列净对伴有和不伴有糖尿病的慢性肾脏病患者的主要不良肾脏和心血管事件的影响：来自 DAPA-CKD 试验的预先指定分析。
Lancet Diabetes Endocrinol. 2021 Jan;9(1):22-31. doi: 10.1016/S2213-8587(20)30369-7.
9
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.SGLT2 抑制剂用于 2 型糖尿病的心血管和肾脏结局的一级和二级预防：心血管结局试验的系统评价和荟萃分析。
Lancet. 2019 Jan 5;393(10166):31-39. doi: 10.1016/S0140-6736(18)32590-X. Epub 2018 Nov 10.
Zotero 插件